To evaluate the relationship of genetic polym orphism s of ERCC2 and ERCC4 genes, both involved in nucleotide excision repair (NER), and the risk of breast cancer, a hospital-based case-control study w as conducted in Korea. Histologically confirm ed breast cancer cases (n = 574) and controls (n = 502) w ith no present or previous history of cancer w ere recruited from three teaching hos- 
Introduction
Breast cancer is the second common malignancy diagnosed among Korean women and the incidence is increasing continuously (National Statistical Office of Korea, 1998) . Although a substantial proportion of breast cancer cases are explained by well-established risk factors (i.e., later age of first birth, nulliparity and first-degree family history of breast cancer) (Madigan et al., 1995) , the reason for the observed worldwide increase in breast cancer incidence is still largely unknown.
Because of the importance of maintaining genomic integrity in carcinogenesis (Seo et al., 2004) , genes coding for DNA repair molecules have been proposed as candidates for modifiers of individual susceptibility to breast cancer (Shields et al., 1991) . This view is supported by previous epidemiological studies suggesting that a combination of genetic polymorphism of DNA repair genes and exposure to genotoxic agents may contribute to breast cancer development (Patel et al., 1997; Goode et al., 2002; .
The nucleotide excision repair (NER) pathway repairs bulky lesions such as pyrimidine dimmers, photoproducts, large chemical adducts, and cross-links (Wood et al., 1997) . The NER pathway involves at least four steps: (a) damage recognition by a complex of bound protein XPC; (b) unwinding of the DNA by the TFIIH complex that includes ERCC2; (c) removal of the damaged single-stranded fragment by molecules including an ERCC1-ERCC4 complex; and (d) synthesis by DNA polymerase (Friedberg et al., 2001 (Winsey et al., 2000) . Although both Asp 312 Asn and Lys 751 Gln are nonsynonymous and related to functional activities (Tang et al., 2002) , Asp 312 Asn locus was selected in this study because Asp 312 Asn polymorphisms has been shown to affect smoking related lung cancer (Hou et al., 2002; Zhou et al., 2002) and breast cancer risk whereas Lys 751 Gln is not associated with breast cancer risk and Asp 312 Asn and Lys 751 Gln in the strong linkage disequilibrium (P .0001) (Justenhoven et al., 2004) .
The ERCC4 has an important role of removing the damaged single-stranded fragment by constructing an ERCC1-ERCC4 complex. (Fan et al., 1999) . A few studies on association between ERCC4 genotypes and cancer proneness was conducted: Ser 835 Ser and melanoma skin cancer (Winsey et al., 2000) and Arg 415 Gln and breast cancer . Since the genotype of frequency of Gln/Gln genotype of codon 415 was very rare (3%) and there was no significant association with breast cancer in Caucasian women, Ser 835 Ser locus of exon 11 was selected in this study.
O ur previous studies suggest that XR CC1 Arg 399 Gln and hOGG1 Ser 326 Cys genotypes may be associated with the risk of breast cancer (Kim et al., 2002; Choi et al., 2003) . Here we extended the study to examine the association between the ERCC2 Asp 312 Asn (G A) and ERCC4 Ser 835 Ser (T C) genotypes and breast cancer risk. These genes and loci were selected on the basis of their functional significance and known allele frequencies (Fan et al., 1999; Winsey et al., 2000; Hou et al., 2002; Tang et al., 2002; Zhou et al., 2002) .
S ubjects and M ethods

Study subjects
The study subjects were recruited from patients admitted to the department of surgery at three teaching hospitals located in Seoul (Seoul National University Hospital, Borame Hospital, and Asan Medical Center) from March 1995 to January 2001 (Lee et al., 2004) . Eligible subjects consisted of a series of histologically confirmed incident breast cancer patients (n = 577) and non-cancer controls (n = 507) from whom blood samples were available. After excluding subjects with previous history of cancer, hysterectomy or oophorectomy, the final study population consisted of 574 cases and 502 controls. The study design was approved by the Committee on Human Research of Seoul National University Hospital. The study subjects gave informed consent prior to participation in the study. Informed consent was obtained from all participants at the time of blood withdrawal.
Information on demographic characteristics, education, marital status, family history of breast cancer, reproductive factors and menstruation, and life style habits (including smoking and alcohol consumption) was collected using a questionnaire administered by trained interviewers.
G enotyping M ethods
DNA was isolated using standard methods from whole blood drawn into 10 ml heparinized tubes and stored in -70 o C until use. The ERCC2 Asp 312 Asn genotype was determined by single base extension assay. Polymerase chain reaction (PCR) product was obtained using 500 nM of oligonucleotide primers (P1: 5'-CCC AGC TCA TCT CTC CGC AGG ATC A-3' and P2: 5'-GGG AGG CGG GAA AGG GAC TG-5') in a total volume of 20 µl. The amplification conditions were: initial denaturation at 95 o C for 5 min followed by 35 cycles of 30 s at 94 o C and 180 s at 72 o C. Primer extension was performed by combining 1 µl of exonuclease I and alkaline phosphatase treated PCR product with 5 µl single base extension kit, 0.15 pmol extension primer (5'-TGG CCA ACC CCG TGC TGC CC-3') and 3 µl water. The reaction mixture was incubated at 94 o C for 2 min prior to PCR of 25 cycles of 95 o C for 5 s, 50 o C for 5 s, and 60 o C for 5 s. Aliquots of 1 µl SNaPshot product and 9 µl Hi-Di formamide, were combined in a 96-well 3100 optical microamp plate, which was loaded onto a 3100 DNA sequencer (Applied Biosystems, Foster city, CA). Reactions were electrophoresed on a 36-cm capillary array at 60 o C by using POP4 polymer, dye set "E" and Genescan run module "SNP36POP4_default." Electrophoresis data were processed by Genescan Analysis version 3.7 (Applied Biosystems, Foster city, CA).
The ERCC4 Ser 835 Ser genotype was determined by dynamic allele-specific hybridization system (DASH, Hybaid). The 61 bp PCR product was obtained from about 10 ng DNA using the following oligonucleotide primers P1: 5'-GGC GAC AGC ACT GGC CAT TAC-3' (20 pmol) and P2: biotin-labeled 5'-ATT ATA CTT CTC TGA CTC GG-3' (4 pmol) (Bioneer: Seoul, Korea) in 20 µl volume PCR reaction. The genotype data could be achieved for 67% of the subjects for ERCC4 and of 93% the subjects for ERCC2. The main reasons for the low success rate were too low amount of DNA and/or unsuccessful PCR amplification.
Statistical analysis
Chi-square test and Fisher's exact test were used to test whether observed genotype data were consistent with Hardy-Weinberg equilibrium and to compare the allele frequencies between cases and controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by unconditional logistic regression model. The ORs were adjusted for age, body mass index (BMI), lifetime estrogen exposure, education and family history of breast cancer. To test the effect of combined genotype, we also carried out a likelihood ratio test for the multiple genotypes grouped by the ERCC2 Asp 312 Asn and ERCC4 Ser 835 Ser polymorphisms. Lifetime estrogen exposure was calculated for premenopausal women by subtracting the menarcheal age and child number and multiplied by 280/365 from the age at interview, and for postmenopausal women subtracting the menarcheal age and child number × 280/365 from the age at menopause (Huang et al., 1999) . To increase the statistical power, the respective genotypes were divided into two groups in the statistical analyses. All analyses were carried out with the SPSS (version 10.0) statistical software package.
R esults and D iscussion
The mean age was 47.9 in cases and 46.9 in controls. Higher education (at and over high school; OR = 2.0, 95% CI: 1.47-2.67), BMI ( 25 kg/m 2 ; OR = 1.5, 95%CI: 1.07-2.02), and family history of breast cancer (OR = 2.4, 95% CI: 1.34-4.40) were significantly associated with breast cancer risk (Table 1) . There was a significant trend of increased risk of the lifetime estrogen exposure increased (P for trend 0.001, Table 1 ).
The frequency of ERCC2 A allele in the present Asian controls (5.3%) was drastically lower than that previous reported in Caucasians (33-44%) (Wensey et al., 2000; Tomescu et al., 2001; Vogel et al., 2001; Hou et al., 2002) , whereas the frequency of ERCC4 C allele (23%) was similar to the frequencies found in UK (23%) (Wensey et al., 2000) and USA (33%) (Fan et al., 1999) . When the ERCC2 and ERCC4 genotypes were studied separately, no significant overall associations with the risk of breast cancer were seen (Table 2) . No association between the ERCC2 Asp 312 Asn polymorphisms and breast cancer observed in this study is consistent with a previous study (Tang et al., 2002) , but not consistent with a recent larger study (Justenhoven et al., 2004) . However, interactive effect was observed between ERCC4 and BMI for the breast cancer risk: the ERCC4 C allele containing genotypes posed a 1.7-fold (95% CI: 0.96-2.93) breast cancer risk in obese women (BMI 25 kg/m 2 ) with a borderline significance. There was no association between ERCC4 genetic polymorphism and BMI (OR = 1.2, 95% CI: 0.89-1.84, data not shown).
Although there is no previous data available on the potential association between ERCC2 genetic polymorphism and breast cancer risk, the present negative finding is similar to the result reported by Fraglia et al. that the ERCC2 genotypes did not significantly affect the formation of 4-aminobiphenyl-DNA adducts in breast tissue (Fraglia et al., 2003) . Although the odds ratio was just statistically borderline significant, the effects of ERCC4 C allele containing genotypes on the risk of breast cancer in women with higher BMI might be explained by the fact that a higher BMI may be associated with higher levels of lipophilic aromatic compounds, stored in breast adipose tissue, leading to a continuous exposure to DNA-damaging agents (Gorlewska-Roberts et al., 2002) . Deficient DNA repair may contribute to the accumulation of damaged DNA unrepaired in both lymphocyte and target tissue.
When the combined genotype effects were examined, women with concurrent presence of ERCC2 A allele and ERCC4 C allele containing genotypes showed a 2.6-fold (95% CI: 1.02-6.48) risk of breast cancer compared to those with ERCC2 GG and ERCC4 TT genotype combination (Table 4 ). The risk of breast cancer increased with the number of "at risk" genotypes, however it was only borderline significance (P for trend = 0.07). This gene-gene interaction may be explained by that ERCC2 opens up the DNA structure and ERCC4 forms a complex with ERCC1 that incises DNA at the 5' side of a bulky adduct lesion (Friedberg et al., 2001) . Genetic variants of ERCC2 and ERCC4 may have a combined effect on breast cancer risk since both ERCC2 and ERCC4 are involved in nucleotide excision repair. In conclusion, our finding suggests that the combined effect of ERCC2 Asp 312 Asn and ERCC4 Ser 835 Ser genotypes may be associated with breast cancer risk. However, a larger study combined with other SNP loci of functional significance (e.g., ERCC2 Lys 751 Gln, ERCC4 5' noncoding region, etc.) is warranted in the future. 
